Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Filings indexed 422 across all filing types
Latest filing 2026-05-18 Report Publication Anno…
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
FORM 8-K
Report Publication Announcement Classification · 90% confidence The document is a Form 8-K current report by Entrada Therapeutics that does not contain substantive financial statements or an investor presentation itself but simply notifies that a corporate presentation is furnished as Exhibit 99.1. It is under 5,000 characters and states that the report is attached, fitting the “Menu vs. Meal” Rule for a Report Publication Announcement rather than the report itself.
2026-05-18 English
10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
Regulatory Filings Classification · 92% confidence The document is a Form 8-K “Current Report” filed with the SEC that furnishes press releases (Exhibits 99.1 and 99.2) regarding quarterly results and clinical study toplines. It does not itself contain the substantive earnings or financial statements but references exhibits and follows SEC 8-K disclosure requirements. This is a regulatory filing rather than the primary financial report or an earnings release text. Hence, it falls under the general Regulatory Filings category (RNS).
2026-05-07 English
ARS - Entrada Therapeutics, Inc. (0001689375) (Filer)
Annual Report
2026-04-24 English
DEF 14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
Proxy Solicitation & Information Statement
2026-04-24 English
4 - ENTRADA THERAPEUTICS, INC. (0001689375) (Filer)
Director's Dealing
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.